Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Change in Account Payables (2017 - 2020)

Historic Change in Account Payables for Fortress Biotech (FBIO) over the last 5 years, with Q4 2020 value amounting to -$19000.0.

  • Fortress Biotech's Change in Account Payables changed N/A to -$19000.0 in Q4 2020 from the same period last year, while for Mar 2021 it was -$6000.0, marking a year-over-year increase of 9776.95%. This contributed to the annual value of -$149000.0 for FY2019, which is 54782.61% down from last year.
  • Latest data reveals that Fortress Biotech reported Change in Account Payables of -$19000.0 as of Q4 2020.
  • Over the past 5 years, Fortress Biotech's Change in Account Payables peaked at $133000.0 during Q1 2019, and registered a low of -$298000.0 during Q3 2019.
  • For the 4-year period, Fortress Biotech's Change in Account Payables averaged around -$15400.0, with its median value being $6000.0 (2018).
  • Within the past 5 years, the most significant YoY rise in Fortress Biotech's Change in Account Payables was 170000.0% (2019), while the steepest drop was 47250.0% (2019).
  • Quarter analysis of 4 years shows Fortress Biotech's Change in Account Payables stood at $24000.0 in 2017, then crashed by 116.67% to -$4000.0 in 2018, then plummeted by 7350.0% to -$298000.0 in 2019, then surged by 93.62% to -$19000.0 in 2020.
  • Its Change in Account Payables stands at -$19000.0 for Q4 2020, versus $13000.0 for Q1 2020 and -$298000.0 for Q3 2019.